Omnicell (OMCL) Stock Analysis & AI Equity Report
Omnicell (OMCL) overview
Omnicell (OMCL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,185m and operating profit of USD 5.2m; the year-end share price was 45.30 USD and market capitalisation was USD 2,040m. Omnicell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Omnicell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Omnicell
Omnicell provides healthcare technology for medication management across care settings. Its offerings combine medication storage and dispensing automation with software and an intelligence ecosystem. Hospital and health system solutions support central pharmacy operations, robotics, sterile compounding, and dispensing in nursing units and procedural areas. Customers include healthcare institutions seeking to support pharmacists and nurses and manage medication workflows.
Generate the Omnicell report
Omnicell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Omnicell and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Omnicell
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.